







We read with great interest the re-
cent article by Katayama et al.1 on the
efficacy of erlotinib for intracranial me-
tastases in patients who had shown a good
response to gefitinib. Even if a substa-
ntial response is obtained with erlotinib as
a readministration of epidermal growth
factor receptor (EGFR)-tyrosine kinase in-
hibitor (TKI), the progression-free interval
is usually not long enough. We present
herein a patient with multiple brain metas-
tases whose lesions were refractory to pre-
vious standard-dose EGFR-TKI therapies
and whole brain radiotherapy (WBRT).
Nevertheless, her brain metastases showed
a remarkable response to “high-dose” er-
lotinib therapy.
A 52-year-old woman without a
history of smoking presented with pro-
ductive cough and progressive dyspnea.
The computed tomography scan re-
vealed bilateral pleural effusion, bilat-
eral innumerable intrapulmonary nod-
ules, and pericardial effusion. Multiple
brain lesions compatible with metastatic
tumors were found with magnetic reso-
nance imaging (MRI) of the brain. Cy-
tologic examination of the pleural fluid
revealed adenocarcinoma, and the pa-
tient was diagnosed with metastatic non-
small cell lung cancer (NSCLC). Simul-
taneously, a sensitive EGFR mutation
(exon 18 G719A) was identified based
on analysis of the malignant effusion.
After chest-tube drainage, gefitinib was
administered, and a partial response was
achieved for approximately 1 year. After
disease progression on gefitinib, the pa-
tient was consecutively treated with sev-
eral chemotherapy regimens. During the
course of therapy, the brain metastases
became symptomatic, and she under-
went WBRT (total of 30 Gy). In the
spring of 2009, erlotinib was adminis-
tered, and disease stability was obtained
for 4 months, followed by a progression
of brain metastases with complaints of
gait disturbance and dysarthria. Elro-
tinib was changed to pemetrexed as the
sixth-line treatment. Nevertheless, 2
weeks after initiation of the agent, her
symptoms further deteriorated. The
brain MRI and body computed tomog-
raphy scan showed a further progression
of brain metastases (Figure 1A), despite
stable extracranial lesions. WBRT had
already been performed and, consider-
ing her heavy treatment history, cyto-
toxic agents seemed to be ineffective for
the brain metastases. Moreover, the
standard dosage of erlotinib had failed
to improve brain lesions several weeks
before. Therefore, we decided to admin-
ister “high-dose erlotinib.” Erlotinib was
given on alternating days at a dose of
300 mg/d. Two weeks after the initiation
of high-dose erlotinib, both her clinical
symptoms and findings of brain MRI im-
proved. Regarding adverse events, a grade
1 rash was observed. Since high-dose er-
lotinib was initiated, her clinical symp-
toms and findings of brain MRI (Figure
1B) have remained stable for 6 months.
WBRT is commonly used as the
primary approach for multiple brain me-
tastases in the treatment of NSCLC. The
efficacy of cytotoxic agents for brain
metastases is considered to be modest
and limited because of the blood brain
barrier. Several authors have recently
reported the utility of small molecule
EGFR-TKIs for brain metastases from
NSCLC, especially in patients with
EGFR mutations.2 Nevertheless, after
the failure of WBRT and the standard
dose of EGFR-TKIs, there has until now
been almost no other approach to con-
trolling brain metastases. In this case,
we adopted high-dose erlotinib to treat
such refractory central nervous system
(CNS) metastases. Two recent reports
have already demonstrated the efficacy
of high-dose EGFR-TKIs for refractory
CNS metastases.3,4 In both reports, after
failure of standard-dose EGFR-TKIs for
CNS metastases, high-dose EGFR-TKIs
were administered, and intracranial le-
sions showed a response. These re-
sponses suggest that the CNS metastases
remained sensitive to high-dose EGFR-
TKIs and that the higher dose led to
higher CNS penetration of the drugs.
High-dose EGFR-TKIs will contribute
to the treatment of refractory CNS me-
tastases after the failure of WBRT and
the standard-dose EGFR-TKIs treat-
ment. Further prospective trials regard-
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FIGURE 1. A, Brain MRI before the initiation of high-dose erlotinib. B, Brain MRI 2
months after the initiation of high-dose erlotinib. MRI, magnetic resonance imaging.
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ing high-dose EGFR-TKIs are war-
ranted for such patients.
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Note to the readership
The letter that was intended by the authors to follow “High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell
Lung Cancer,” which appears in the current issue of the journal, has been published in a previous issue. This letter, “Does the Addition of Vascular
Endothelial Growth Factor Inhibitors to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Overcome T790M Acquired Resistance?,” can be
found in the February 2011 issue of the Journal.
Hata A, Kaji R, Fujita S, Katakami N: Does the Addition of Vascular Endothelial Growth Factor Inhibitors to Epidermal Growth Factor Receptor-
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